ABBV-744

Catalog No.S8723 Batch:S872301

Print

Technical Data

Formula

C28H30FN3O4
Molecular Weight 491.55 CAS No. 2138861-99-9
Solubility (25°C)* In vitro DMSO 98 mg/mL (199.36 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5% DMSO 95% Corn oil
0.615mg/ml Taking the 1 mL working solution as an example, add 50 μL of 12.3 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
4.9mg/ml Taking the 1 mL working solution as an example, add 50 μL of 98 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2, BRD3 and BRD4. It is developed for treating AML and cancers.
Targets
BDII [1]
In vitro

ABBV-744 is a potent inhibitor specific for BDII of BRD2/3/4, with >250-fold differential binding preference for BDII over BDI and excellent drug-like properties. ABBV-744 is also a potent and selective inhibitor of the AR (androgen receptor) transcription pathway[1].
In vivo

In vivo, doses of ABBV-744 at fractions of its maximum tolerated dose (MTD) induces tumor growth inhibition in AML and prostate cancer xenograft models that were comparable to those observed with ABBV-075 when dosed at its MTD[1].

Protocol (from reference)

Animal Study:

[2]
  • Animal Models

    Male Sprague-Dawley (SD) rats

  • Dosages

    60 mg/kg

  • Administration

    o.g.

Selleck's ABBV-744 has been cited by 10 publications

Synergistic Sensitization of High-Grade Serous Ovarian Cancer Cells Lacking Caspase-8 Expression to Chemotherapeutics Using Combinations of Small-Molecule BRD4 and CDK9 Inhibitors [ Cancers (Basel), 2023, 16(1)107] PubMed: 38201534
Selective BD2 Inhibitor Exerts Anti-Fibrotic Effects via BRD4/FoxM1/Plk1 Axis in Orbital Fibroblasts From Patients With Thyroid Eye Disease [ Invest Ophthalmol Vis Sci, 2023, 64(7):9] PubMed: 37272763
BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2 [ Nat Cell Biol, 2022, 24(1):24-34] PubMed: 35027731
Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators [ Biomed Pharmacother, 2022, 152:113230] PubMed: 35687908
Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer [ J Cancer Res Clin Oncol, 2022, 148(4):803-821] PubMed: 35094142
Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer [ J Cancer Res Clin Oncol, 2022, 10.1007/s00432-021-03885-z] PubMed: 35094142
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma [ Cancer Chemother Pharmacol, 2022, 89(5):643-653] PubMed: 35381875
BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2 [ bioRxiv, 2021, 2021.01.19.427194] PubMed: 33501440
Viral E Protein Neutralizes BET Protein-Mediated Post-Entry Antagonism of SARS-CoV-2 [ bioRxiv, 2021, 2021.11.14.468537] PubMed: 34816261
BRD4 Prevents R-Loop Formation and Transcription-Replication Conflicts by Ensuring Efficient Transcription Elongation [ Cell Rep, 2020, 32(12):108166] PubMed: 32966794

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.